Kidney disease consensus manuscript published: highlights the need to improve awareness of racial health disparities

19 May 2021

Share this page

Share this page on LinkedIn

Oxford PharmaGenesis is proud to announce the publication of a Delphi consensus manuscript in the Journal of the American Society of Nephrology. The publication highlights the need to increase awareness among key stakeholders of racial health disparities in kidney disease and of APOL1-associated nephropathy.

The publication follows months of impressive collaboration with a diverse group of experts and representative patient and community stakeholders.

Health disparities

End-stage kidney disease affects three times as many black people as white people. Social determinants of health, racism and genetic factors are understood to contribute to this disparity.

Genetic factors include variants of the APOL1 gene found almost exclusively in people with recent West African ancestry, however no specific treatment or management protocol for APOL1-associated nephropathy exists.

This manuscript shares findings from a multidisciplinary, racially diverse group of 14 experts and patient advocates who participated in a Delphi consensus process to establish practical guidance for clinicians caring for patients who may have APOL1-associated nephropathy.

The group achieved consensus on the need to increase awareness among key stakeholders of racial health disparities in kidney disease and of APOL1-associated nephropathy, and on features of a successful education programme to raise awareness among the patient community.

The group also highlighted the unmet need for a specific treatment and agreed on best practice for management of these patients should a treatment become available.

Specialist support

The consensus guidance is endorsed by the Renal Association, NephCure Kidney International and the Texas Kidney Foundation. It is further supported by the American Kidney Fund  and the American Society of Diagnostic and Interventional Nephrology.

This initiative was funded by an educational grant from AstraZeneca.

Oxford PharmaGenesis is proud to be part of this important work, which is in line with our commitment to equity, diversity and inclusivity.

Please click here to read the consensus and to share it with your own communities.